Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InViVoCAR1920 mRNA
- Development stage
- Phase 2
- Lead developer
- Daihong Liu
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
InViVoCAR1920 mRNA is an experimental *in vivo* CAR-T cell therapy being developed for the treatment of relapsed or refractory B-cell lymphoma and leukemia. The therapy utilizes polymer-lipid nanoparticles (PLNs) to deliver mRNA encoding a dual-targeting chimeric antigen receptor (CAR) that simultaneously targets CD19 and CD20 antigens on the surface of malignant B cells. Unlike conventional CAR-T therapies that require complex *ex vivo* genetic modification of a patient's T cells, InViVoCAR1920 mRNA is designed to reprogram T cells directly within the patient's body. This approach aims to simplify the manufacturing process, reduce treatment wait times, and mitigate the risk of antigen escape by targeting two distinct B-cell markers.
- Other names
- CD19/CD20 dual-targeting InViVoCAR1920 mRNAPolymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 mRNA
02
Targets
Beyond the preview
Go deeper on InViVoCAR1920 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InViVoCAR1920 mRNA.